Tumor necrosis factor-alpha inhibits collagen alpha1(I) gene expression and wound healing in a murine model of cachexia
M Buck, K Houglum, M Chojkier, M Buck, K Houglum, M Chojkier
Abstract
The mechanisms responsible for impaired wound healing in patients with cachexia-associated infection, inflammation, and cancer are unknown. As tumor necrosis factor (TNF)-alpha is elevated in these diseases, and TNF-alpha inhibits collagen alpha1(I) gene expression in cultured fibroblasts, we analyzed whether chronically elevated serum TNF-alpha affects collagen metabolism in vivo by inoculating nude mice with Chinese hamster ovary cells secreting TNF-alpha (TNF-alpha mice) or control Chinese hamster ovary cells (control mice). Before the onset of weight loss, TNF-alpha mice had a selective decrease in collagen synthesis and collagen alpha1(I) mRNA in the skin. In addition, TNF-alpha mice displayed impaired healing of incisional and excisional skin wounds, compared with control animals, before the onset of cachexia. The expression of transforming growth factor-beta1, a potent fibrogenic factor, was inhibited by TNF-alpha in the skin. In studies with transgenic mice expressing the human growth hormone under the direction of 5' regulatory regions of the human collagen alpha1(I) gene, TNF-alpha treatment inhibited the expression of the collagen alpha1(I) human growth hormone transgene containing -2.3 kb of the 5' region, whereas transgene expression directed by -0.44 kb of the 5' region was not affected. These experiments suggest that TNF-alpha may play an important role in the impaired wound healing of chronic diseases that are characterized by a high production of this cytokine and provide insights for potential therapeutic approaches.
References
- J Exp Med. 1986 Jun 1;163(6):1433-50
- J Biol Chem. 1985 Apr 10;260(7):3955-62
- J Clin Invest. 1986 Aug;78(2):333-9
- Lancet. 1986 Dec 13;2(8520):1364-5
- Lancet. 1987 Feb 14;1(8529):355-7
- J Trauma. 1994 Jun;36(6):810-3; discussion 813-4
- N Engl J Med. 1994 Nov 10;331(19):1286-92
- Am J Physiol. 1994 Nov;267(5 Pt 1):G908-13
- J Clin Invest. 1995 Jul;96(1):250-9
- J Biol Chem. 1987 May 15;262(14):6443-6
- Cell. 1987 Aug 14;50(4):555-63
- Science. 1987 Sep 11;237(4820):1333-6
- Nature. 1987 Oct 15-21;329(6140):630-2
- Biochem J. 1987 Nov 1;247(3):597-604
- J Cell Biol. 1988 Feb;106(2):311-8
- Cell. 1988 Feb 12;52(3):405-14
- J Exp Med. 1988 Mar 1;167(3):1211-27
- Am J Med. 1988 Sep;85(3):289-91
- Hepatology. 1988 Sep-Oct;8(5):1040-5
- Nature. 1989 Feb 16;337(6208):661-3
- N Engl J Med. 1989 Jun 15;320(24):1586-91
- J Exp Med. 1989 Sep 1;170(3):655-63
- J Cell Biol. 1990 Jan;110(1):133-45
- J Clin Invest. 1990 Jan;85(1):248-55
- Nature. 1990 Mar 15;344(6263):245-7
- Ann N Y Acad Sci. 1990;593:208-17
- Clin Plast Surg. 1990 Jul;17(3):433-42
- FASEB J. 1990 Aug;4(11):2860-7
- J Clin Invest. 1990 Nov;86(5):1489-95
- Genes Dev. 1990 Sep;4(9):1541-51
- N Engl J Med. 1991 Apr 4;324(14):933-40
- Mol Cell Biol. 1991 Apr;11(4):2066-74
- J Invest Dermatol. 1991 Jul;97(1):34-42
- Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6642-6
- J Clin Invest. 1991 Sep;88(3):904-10
- Biochem J. 1991 Nov 15;280 ( Pt 1):157-62
- J Biol Chem. 1992 Jul 15;267(20):14316-21
- J Clin Invest. 1992 Jul;90(1):1-7
- Surgery. 1993 Feb;113(2):173-7
- Am J Pathol. 1993 Aug;143(2):368-80
- EMBO J. 1993 Aug;12(8):3095-104
- J Clin Invest. 1993 Dec;92(6):2565-6
- J Clin Invest. 1993 Dec;92(6):2841-9
- Annu Rev Cell Biol. 1993;9:317-43
- J Cell Biol. 1994 May;125(3):695-704
- Nature. 1970 Aug 15;227(5259):680-5
- Cell. 1982 Jun;29(2):661-9
- J Clin Invest. 1983 Sep;72(3):826-35
- J Cell Biol. 1984 Jun;98(6):2091-106
- Gastroenterology. 1985 Jan;88(1 Pt 1):115-21
- Proc Natl Acad Sci U S A. 1986 Jun;83(12):4167-71
Source: PubMed